{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"12.670","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"971,195,697","primaryexch":"香港交易所","ric":"9966.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.1729,"inline_upper_strike_price":"","sedol":"BL6WGG4","am":"36.47","iv":"","ew_strike":"","as":"12.400","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"12.270","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"1,000","update_time":"2025-09-28 00:06:03.0","lo52":"2.580","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"徐霆","underlying_ric":"9966.HK","hi52":"13.390","issuer_name":"康寧傑瑞生物製藥 - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"12.080","mkt_cap":"11.91","f_aum_hkd":null,"ew_sub_per_to":"","ls":"12.270","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.390","aum":"","issued_shares_class_B":null,"vo":"2.94","secondary_listing_flag":false,"listing_date":"2019年12月12日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"康寧傑瑞生物製藥 - B","nm_s":"康寧傑瑞製藥－Ｂ","sym":"9966","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"康寧傑瑞生物製藥是一家主要從事腫瘤生物製劑研發、製造及商業化的投資控股公司。該公司高度差異化的內部管線由處於不同研發階段的ADCs、單克隆抗體及雙特異性抗體腫瘤藥物組成。該公司的候選藥物包括KN046（PD-L1/CTLA-4雙特異性抗體）, KN026（抗HER2雙特異性抗體）, KN035（皮下注射PD-L1）, JSKN003（HER2雙表位ADC）等，用于1L sq NSCLC、乳腺癌2+HER L1、晚期實體瘤、HER2表達實體瘤等適應症。","op":"12.600","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港銅鑼灣<br/>希慎道33號<br/>利園一期<br/>19樓1901室","pc":"-3.08","days_to_expiry":null,"underlying_code":null,"pe":"67.01","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"12.660","isin":"KYG0330A1013","moneyness":""}},"qid":"1759074253525"}
